Objective derivation of the morphology and staging of visual field loss associated with long-term vigabatrin therapy

Video 1: Video of the rolling median of the 78 modelled fields from the 87 individuals who had been exposed to vigabatrin and who had undertaken the Full Field 135 Point Test with the three zone age-corrected strategy. Video 2: Video of the rolling median of the 90 modelled fields from the 99 individuals who had been exposed to vigabatrin and who had undertaken the Central 30-2 Threshold Test. Video 3: Video of the rolling median of the 54 modelled fields from the 63 individuals who had been exposed to vigabatrin and who had undertaken the combined Full Field 135 Point Test with the three zone age-corrected strategy and the Central 30-2 Threshold Test. Video 4: Video of the rolling median of the 29 modelled fields from the 38 individuals with no exposure to vigabatrin and who had undertaken the combined Full Field 135 Point Test with the three zone age-corrected strategy and the Central 30-2 Threshold Test. Disclosures Funding None Conflicts of interest John M Wild, Phillip EM Smith and Carlo Knupp declare that they have no conflicts of interest. Ethical approval All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Local Research and Ethics Committee ruled that approval was not required for this study. The visual field assessments were considered to be part of normal good clinical practice. The visual fields were de-identified and so written informed consent was not required. Data availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. Copyright This video is distributed under the terms of the Creative Commons Attribution Noncommerical Licence which permits any noncommerical use, distribution, and reproduction in any medium, provided the original author(s) and the source is credited.视频1：展示了87名暴露于氨己烯酸（vigabatrin）且采用三区年龄校正策略完成全视野135点测试（Full Field 135 Point Test）的受试者所建模的78个视野数据的滚动中位数可视化视频。视频2：展示了99名暴露于氨己烯酸且完成中心30-2阈值测试（Central 30-2 Threshold Test）的受试者所建模的90个视野数据的滚动中位数可视化视频。视频3：展示了63名暴露于氨己烯酸且同时完成三区年龄校正策略全视野135点测试与中心30-2阈值测试的受试者所建模的54个视野数据的滚动中位数可视化视频。视频4：展示了38名未暴露于氨己烯酸且同时完成三区年龄校正策略全视野135点测试与中心30-2阈值测试的受试者所建模的29个视野数据的滚动中位数可视化视频。 资助声明：无 利益冲突声明：John M Wild、Phillip EM Smith与Carlo Knupp声明无任何利益冲突。 伦理审批：本研究涉及人类受试者的所有操作均符合1964年《赫尔辛基宣言》（1964 Helsinki declaration）及其后续修正案或同等伦理标准。当地研究伦理委员会裁定本研究无需正式伦理审批；视野检查被认定为常规临床诊疗的一部分，且所有视野数据均已去标识化，因此无需获取受试者书面知情同意。 数据可用性：本研究中生成及/或分析的数据集可根据合理请求，向通讯作者获取。 版权声明：本视频采用知识共享署名-非商业性使用许可协议（Creative Commons Attribution Noncommercial Licence）分发，允许在注明原作者及来源的前提下，以任何媒介进行非商业性使用、传播与复制。